Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation
ResearchMoz presents professional and in-depth study of "Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation".
The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and present a major global health burden. Across the pharmaceutical industry as a whole, the oncology pipeline is far larger than any other therapy area, with 6,484 products in active development across all oncology indications, and 2,084 first-in-class products in development across all stages.
Due to a degree of crossover between oncology indications in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications. Some 473 first-in-class pipeline products are in concurrent development for two or more of the top 20 cancer sites ranked by incidence. The most promising versatile first-in-class molecular targets predominantly consist of receptor tyrosine kinases and their downstream signal transduction kinases, although a number of other cancer-related processes such as DNA repair, cancer immunosurveillance and apoptotic pathways are also targeted.
Scope
With 6,484 products in active development across all oncology indications, this is the largest therapy area pipeline by a considerable margin.
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=316439
What factors are driving this high level of R&D activity?
Which indications have the highest concentration of pipeline products?
Although the unmet need varies between and within indications, this need is primarily for improved overall survival rates in patients, particularly those at the late stage of the disease.
Which first-in-class molecular targets appear able to best address the key unmet needs within oncology?
The variation in molecule type has shifted away from small molecules, the dominance of which has decreased from 94% across marketed products to 49% across the pipeline.
What are the dynamics of the remaining 51% of the pipeline?
How does this reflect the need for novel targeted therapies?
There has been a significant shift towards inhibitors of receptor tyrosine kinases, their ligands and signal transduction proteins, as well as drugs targeted against cancer antigens.
What is the scientific rationale behind these targets? Across which indications are they being developed?
How successful have drugs against these targets been?
A number of versatile first-in-class targets appear to be particularly promising, including HER3, FGFR3, telomerase reverse transcriptase, and others.
Why are these targets considered to be particularly promising?
Why are these targets being developed across such a wide range of indications?
Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 A Large Therapy Area with Varying Unmet Needs Across Indications 5
2.2 A Large Pipeline with a High Degree of First-in-Class Innovation 5
2.3 A Number of Highly Promising First-in-Class Versatile Oncology Pipeline Targets 5
3 The Case for Innovation in the Oncology Market 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 Report Guidance 9
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=316439
4 Clinical and Commercial Landscape 10
4.1 Therapy Area Overview 10
4.1.1 Epidemiology 10
4.1.2 Etiology 14
4.1.3 Pathophysiology 15
4.1.4 Diagnosis 21
4.1.5 Prognosis and Disease Staging 22
4.2 Treatment Options 24
4.2.1 Surgery and Radiation Therapy 24
4.2.2 Chemotherapy 27
4.2.3 Hormonal Therapies 28
4.2.4 Targeted Therapies 29
4.3 Overview of Marketed Products for Oncology 30
4.4 Current Unmet Needs across the Oncology Markets 32
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://latestmedicalrelatedresearchreport.blogspot.in/
The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and present a major global health burden. Across the pharmaceutical industry as a whole, the oncology pipeline is far larger than any other therapy area, with 6,484 products in active development across all oncology indications, and 2,084 first-in-class products in development across all stages.
Due to a degree of crossover between oncology indications in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications. Some 473 first-in-class pipeline products are in concurrent development for two or more of the top 20 cancer sites ranked by incidence. The most promising versatile first-in-class molecular targets predominantly consist of receptor tyrosine kinases and their downstream signal transduction kinases, although a number of other cancer-related processes such as DNA repair, cancer immunosurveillance and apoptotic pathways are also targeted.
Scope
With 6,484 products in active development across all oncology indications, this is the largest therapy area pipeline by a considerable margin.
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=316439
What factors are driving this high level of R&D activity?
Which indications have the highest concentration of pipeline products?
Although the unmet need varies between and within indications, this need is primarily for improved overall survival rates in patients, particularly those at the late stage of the disease.
Which first-in-class molecular targets appear able to best address the key unmet needs within oncology?
The variation in molecule type has shifted away from small molecules, the dominance of which has decreased from 94% across marketed products to 49% across the pipeline.
What are the dynamics of the remaining 51% of the pipeline?
How does this reflect the need for novel targeted therapies?
There has been a significant shift towards inhibitors of receptor tyrosine kinases, their ligands and signal transduction proteins, as well as drugs targeted against cancer antigens.
What is the scientific rationale behind these targets? Across which indications are they being developed?
How successful have drugs against these targets been?
A number of versatile first-in-class targets appear to be particularly promising, including HER3, FGFR3, telomerase reverse transcriptase, and others.
Why are these targets considered to be particularly promising?
Why are these targets being developed across such a wide range of indications?
Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 A Large Therapy Area with Varying Unmet Needs Across Indications 5
2.2 A Large Pipeline with a High Degree of First-in-Class Innovation 5
2.3 A Number of Highly Promising First-in-Class Versatile Oncology Pipeline Targets 5
3 The Case for Innovation in the Oncology Market 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 Report Guidance 9
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=316439
4 Clinical and Commercial Landscape 10
4.1 Therapy Area Overview 10
4.1.1 Epidemiology 10
4.1.2 Etiology 14
4.1.3 Pathophysiology 15
4.1.4 Diagnosis 21
4.1.5 Prognosis and Disease Staging 22
4.2 Treatment Options 24
4.2.1 Surgery and Radiation Therapy 24
4.2.2 Chemotherapy 27
4.2.3 Hormonal Therapies 28
4.2.4 Targeted Therapies 29
4.3 Overview of Marketed Products for Oncology 30
4.4 Current Unmet Needs across the Oncology Markets 32
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://latestmedicalrelatedresearchreport.blogspot.in/
Comments
Post a Comment